TVTX Travere Therapeutics Inc

$34.69

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/21/2025

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.

Website: https://www.travere.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1438533
Address
777 THIRD AVENUE 22ND FLOOR, NEW YORK, NY, US
Valuation
Market Cap
$1.32B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
22.42
Performance
EPS
$-4.07
Dividend Yield
—
Profit Margin
-137.90%
ROE
-246.70%
Technicals
50D MA
$19.33
200D MA
$16.03
52W High
$25.29
52W Low
$5.12
Fundamentals
Shares Outstanding
89M
Target Price
$33.67
Beta
0.84

TVTX EPS Estimates vs Actual

● Estimated
● Actual

TVTX News & Sentiment

Nov 18, 2025 • Motley Fool SOMEWHAT-BULLISH
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally
A healthcare hedge fund just locked in gains on one of its biggest winners-here's what that move really signals.
Nov 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Oct 31, 2025 • Benzinga SOMEWHAT-BULLISH
Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter - Paranovus Entertainment ( NASDAQ:PAVS ) , Alphatec Holdings ( NASDAQ:ATEC )
As of Oct. 31, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Oct 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Travere Therapeutics ( TVTX ) Beats Q3 Earnings and Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of +190.32% and +59.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 16, 2025 • Benzinga NEUTRAL
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Novartis ( NYSE:NVS )
Novartis A/S ( NYSE:NVS ) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta ( iptacopan ) in adults with IgA nephropathy ( IgAN ) .
Oct 16, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Sentiment Snapshot

Average Sentiment Score:

0.157
50 articles with scored sentiment

Overall Sentiment:

Bullish

TVTX Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.4 Surprise
  • Reported EPS: $0.13
  • Estimate: $-0.27
  • Whisper: —
  • Surprise %: 147.9%
May 01, 2025
Mar 31, 2025 (Pre market)
0.2 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: 51.8%
Feb 20, 2025
Dec 31, 2024 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.47
  • Estimate: $-0.38
  • Whisper: —
  • Surprise %: -24.1%
Oct 31, 2024
Sep 30, 2024 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.68
  • Whisper: —
  • Surprise %: -2.9%
Aug 01, 2024
Jun 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.91
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -5.8%
May 06, 2024
Mar 31, 2024 (Post market)
-0.77 Surprise
  • Reported EPS: $-1.76
  • Estimate: $-0.99
  • Whisper: —
  • Surprise %: -77.8%
Feb 15, 2024
Dec 31, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $-1.18
  • Estimate: $-1.27
  • Whisper: —
  • Surprise %: 7.1%
Nov 07, 2023
Sep 30, 2023 (Post market)
-1.03 Surprise
  • Reported EPS: $-1.17
  • Estimate: $-0.14
  • Whisper: —
  • Surprise %: -735.7%
Aug 03, 2023
Jun 30, 2023 (Post market)
0.03 Surprise
  • Reported EPS: $-1.13
  • Estimate: $-1.16
  • Whisper: —
  • Surprise %: 2.6%

Financials